PCVX - Vaxcyte, Inc. Stock Price, Fair Value and News

$111.21+0.13 (+0.12%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PCVX RSI Chart

PCVX Valuation

Market Cap

12.4B

Price/Earnings (Trailing)

-24.96

Price/Sales (Trailing)

1.7K

Price/Free Cashflow

-25.18

PCVX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PCVX Fundamentals

PCVX Revenue

Revenue (TTM)

4.8M

Rev. Growth (Yr)

-84.01%

Rev. Growth (Qtr)

96.75%

PCVX Earnings

Earnings (TTM)

-497.2M

Earnings Growth (Yr)

-88.33%

Earnings Growth (Qtr)

-35.45%

PCVX Price Action

Last 7 days

-1.7%

Last 30 days

1.9%

Last 90 days

43.0%

Trailing 12 Months

127.2%

PCVX Profitability

Return on Equity

-25.03%

Return on Assets

-23.82%

Free Cashflow Yield

-3.97%

PCVX Financial Health

Current Ratio

17.88

PCVX Investor Care

Shares Dilution (1Y)

18.93%

Diluted EPS (TTM)

-4.68

PCVX Alerts

5 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	2.4M	4.2M	5.7M	4.8M
2022	1.7M	2.1M	1.9M	1.9M
2021	0	2.5M	1.8M	1.9M
2020	797.3K	1.4M	1.9M	2.5M
2019	0	0	0	237.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

CEO	Mr. Grant E. Pickering M.B.A.
WEBSITE	https://vaxcyte.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	158

Vaxcyte, Inc. Frequently Asked Questions

What is the ticker symbol for Vaxcyte, Inc.? What does PCVX stand for in stocks?

PCVX is the stock ticker symbol of Vaxcyte, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaxcyte, Inc. (PCVX)?

As of Fri Oct 04 2024, market cap of Vaxcyte, Inc. is 12.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PCVX stock?

You can check PCVX's fair value in chart for subscribers.

Is Vaxcyte, Inc. a good stock to buy?

The fair value guage provides a quick view whether PCVX is over valued or under valued. Whether Vaxcyte, Inc. is cheap or expensive depends on the assumptions which impact Vaxcyte, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PCVX.

What is Vaxcyte, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Oct 04 2024, PCVX's PE ratio (Price to Earnings) is -24.96 and Price to Sales (PS) ratio is 1.73 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PCVX PE ratio will change depending on the future growth rate expectations of investors.